1-Phenethylamine, (+)- → (7bR,11aS)-N-[(1R)-1-phenylethyl]-1,2,7b,8,9,10,11,11a-octahydro-4H-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indol-6-amine
반응식
[CH3:1][C@@H:2]([NH2:9])[C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][CH:4]=1.Br[C:11]1[CH:12]=[C:13]2[C:17]3=[C:18]([CH2:20][S:21][CH2:22][CH2:23][N:16]3[C@H:15]3[CH2:24][CH2:25][N:26](C(OC(C)(C)C)=O)[CH2:27][C@@H:14]23)[CH:19]=1>>[C:3]1([C@H:2]([NH:9][C:11]2[CH:12]=[C:13]3[C:17]4=[C:18]([CH2:20][S:21][CH2:22][CH2:23][N:16]4[C@H:15]4[CH2:24][CH2:25][NH:26][CH2:27][C@@H:14]34)[CH:19]=2)[CH3:1])[CH:8]=[CH:7][CH:6]=[CH:5][CH:4]=1참가 물질
3
반응물 2
생성물 1
실험 절차
Using (R)-(−)-α-methylbenzylamine and following the procedures described in EXAMPLE 168, tert-butyl (7bR,11aS)-6-bromo-1,2,7b,10,11,11a-hexahydro-4H-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indole-9(8H)-carboxylate from EXAMPLE 7, Part A was converted into the title compound of EXAMPLE 170. 1H NMR(CDCl3) δ: 7.40-7.20 (m, 5H), 6.17 (d, 1H, J=2.2 Hz), 6.10 (d, 1H, J=2.2 Hz), 4.35 (q, 1H, J=6.6 Hz), 3.56 (ABq, 2H, JAB=15.7 Hz), 3.50-3.42 (m, 1H), 3.29-3.21 (m, 2H), 3.15-2.80 (m, 5H), 2.58-2.48 (m, 1H), 2.00-1.85 (m, 2H), 1.45 (d, 3H, J=6.6 Hz). LRMS (ES)+: 366.4 (M+H)+.